February 8, 2016
In a randomized phase 3 study, children and adolescents with chronic hepatitis B virus infection treated with Baraclude showed reduced infection compared with children treated with placebo, according to published findings.
Researchers randomly assigned 180 treatment-naive children and adolescents to a regimen of Baraclude (entecavir, Bristol-Myers Squibb; n = 120) or placebo (n = 60) for a duration of 48 weeks. The primary endpoint of the study was hepatitis B e antigen (HBeAg) seroconversion and reduced HBV DNA levels (less than 50 IU/mL) at 48 weeks. Follow-up was through 96 weeks.